Kathrin Kalies Selected Research

Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa)

12/2020	Propranolol Is an Effective Topical and Systemic Treatment Option for Experimental Epidermolysis Bullosa Acquisita.
1/2020	Epidermal Damage Induces Th1 Polarization and Defines the Site of Inflammation in Murine Epidermolysis Bullosa Acquisita.
1/2018	Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.
12/2017	Nanoparticles prepared from porcine cells support the healing of cutaneous inflammation in mice and wound re-epithelialization in human skin.
12/2017	Evidence for a contributory role of a xenogeneic immune response in experimental epidermolysis bullosa acquisita.
11/2017	CCL3/MIP1α represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisita.
2/2017	Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.
1/2017	The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita.
1/2017	Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation.
12/2016	T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathrin Kalies Research Topics

Disease

18	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 12/2020 - 11/2011
12	Inflammation (Inflammations) 05/2022 - 01/2016
9	Autoimmune Diseases (Autoimmune Disease) 05/2022 - 09/2012
8	Blister (Bulla) 01/2020 - 09/2013
5	Skin Diseases (Skin Disease) 12/2020 - 01/2013
3	Infections 01/2018 - 02/2012
3	Vesiculobullous Skin Diseases (Subcorneal Pustular Dermatosis) 04/2015 - 02/2013
2	Bullous Pemphigoid (Pemphigoid) 01/2018 - 01/2017
2	Tertiary Lymphoid Structures 01/2018 - 02/2011
2	Colitis 11/2017 - 11/2013
1	Sleep Deprivation 05/2020
1	Microscopic Polyangiitis 01/2018
1	Vasculitis (Vasculitides) 01/2018
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2018
1	Virus Diseases (Viral Diseases) 12/2017
1	Neoplasms (Cancer) 12/2017
1	Carcinogenesis 08/2017
1	Colorectal Neoplasms (Colorectal Cancer) 08/2017
1	Ulcerative Colitis 08/2017
1	Disease Progression 02/2017
1	Bacterial Infections (Bacterial Infection) 01/2016
1	Pneumococcal Infections 01/2016
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2013
1	Rheumatoid Arthritis 02/2013
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2012
1	Lupus Nephritis 04/2012
1	Nephritis 04/2012

Drug/Important Bio-Agent (IBA)

15	AutoantibodiesIBA 05/2022 - 04/2012
11	Collagen Type VIIIBA 01/2020 - 11/2011
7	CytokinesIBA 01/2020 - 02/2012
4	Antigen-Antibody Complex (Immune Complex)IBA 12/2020 - 04/2012
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2011
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2020 - 12/2016
3	Immunoglobulin G (IgG)IBA 12/2017 - 04/2012
2	AutoantigensIBA 01/2020 - 01/2018
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 11/2017 - 11/2013
2	Dextrans (Dextran)FDA Link 11/2017 - 11/2013
2	AntibodiesIBA 02/2017 - 11/2011
2	Interleukin-6 (Interleukin 6)IBA 04/2015 - 02/2013
1	Propranolol (Inderal)FDA LinkGeneric 12/2020
1	Myeloblastin (Proteinase 3)IBA 01/2018
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2018
1	Peroxidase (Myeloperoxidase)IBA 01/2018
1	Therapeutic UsesIBA 12/2017
1	Fingolimod Hydrochloride (FTY720)FDA Link 12/2017
1	Biomarkers (Surrogate Marker)IBA 11/2017
1	Etanercept (Enbrel)FDA Link 02/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2017
1	Matrix Metalloproteinases (MMPs)IBA 01/2017
1	tanespimycin (17AAG)IBA 01/2017
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 01/2017
1	Chemotactic FactorsIBA 01/2017
1	EnzymesIBA 01/2017
1	Leukotriene B4IBA 01/2017
1	LipidsIBA 01/2017
1	IgG Receptors (Fc gamma RI)IBA 01/2017
1	anti-type VII collagen autoantibodyIBA 01/2017
1	Interleukin-10 (Interleukin 10)IBA 01/2016
1	AnaphylatoxinsIBA 01/2016
1	Interleukin-10 ReceptorsIBA 01/2016
1	Member 1 Group F Nuclear Receptor Subfamily 1IBA 09/2015
1	Interleukin-1 (Interleukin 1)IBA 04/2015
1	Transcription Factors (Transcription Factor)IBA 11/2013
1	Mitochondrial DNA (mtDNA)IBA 11/2013
1	Adenosine Triphosphate (ATP)IBA 11/2013
1	Trinitrobenzenesulfonic AcidIBA 11/2013
1	SaltsIBA 09/2013
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2013
1	Complement System Proteins (Complement)IBA 11/2011
1	Type I Tumor Necrosis Factor ReceptorsIBA 02/2011

Therapy/Procedure

1	Oral Administration 11/2017
1	Therapeutics 04/2015